SOD1 G93A

Superoxide dismutase 1 (SOD1) is an enzyme that protects cells from oxidative damage by converting harmful superoxide radicals into less dangerous molecules. Mutations in the SOD1 gene are the second most common genetic cause of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease where motor neurons controlling voluntary muscle movement gradually die [2][3][6]. The G93A mutation is among the most extensively studied SOD1 variants associated with ALS, though the disease phenotype can vary considerably even among patients carrying identical mutations [6][7]. The AlphaFold2 structural prediction for SOD1 G93A shows exceptionally high confidence across the entire protein, with an average pLDDT score of 97.7. This indicates that the computational model reliably captures the protein's three-dimensional structure and suggests that the G93A mutation does not dramatically disrupt the overall protein architecture. This finding is consistent with the prevailing scientific understanding that SOD1 mutations cause disease not by destroying the protein's basic structure, but through more subtle mechanisms such as promoting protein instability, misfolding, and toxic aggregation into amyloid-like fibrils [5][8]. The disease mechanism in SOD1-ALS involves the mutant protein forming abnormal aggregates that accumulate in motor neurons. Research has shown that various SOD1 mutations, including those affecting similar structural regions, can destabilize the protein's native fold and promote the formation of beta-sheet-rich amyloid structures that are toxic to neurons [5]. Additionally, emerging evidence points to altered microglial function and impaired cellular clearance mechanisms as contributing factors in disease progression in SOD1 mouse models [1]. The high structural confidence of this prediction makes it a valuable starting point for understanding these pathological processes at the atomic level. Clinically, SOD1 mutations account for approximately 2% of all ALS cases but show variable penetrance and age of onset across different mutations [6][8]. Some SOD1 variants can present with atypical features, such as predominant upper motor neuron involvement rather than the more common lower motor neuron phenotype [7], or even juvenile-onset rapid progression in certain cases [4]. The availability of mutation-specific therapies like tofersen, an antisense oligonucleotide designed to reduce SOD1 protein levels, has made genetic testing increasingly important for treatment planning [3][8]. However, complete understanding of how specific mutations like G93A lead to selective motor neuron death remains an active area of investigation, with hypotheses focusing on toxic gain-of-function mechanisms involving protein aggregation, oxidative stress, and neuroinflammation.